Physician profile
Ashwin Koshy
NPI 1083141360
$5,350.53
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $229 · 2021: $193 · 2022: $974 · 2023: $1,432 · 2024: $2,398 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,643.28 | 2021-2024 | Tezspire, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $872.44 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Viiv Healthcare Company | $741.79 | 2022-2024 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $690.23 | 2021-2024 | Biktarvy |
| Lilly USA, LLC | $374.97 | 2024-2025 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $250.00 | 2024 | Voquezna |
| Novo Nordisk INC | $144.27 | 2020-2023 | Wegovy |
| Amgen INC. | $142.55 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.33 | 2020-2024 | Jardiance |
| Genzyme Corporation | $125.00 | 2023 | |
| Alkermes, INC. | $120.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $64.52 | 2020 | |
| Exact Sciences Corporation | $29.17 | 2024 | Cologuard Collection Kit |
| Biodelivery Sciences International, INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Koshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.